JINAN AISI PHARMACEUTICAL TECHNOLOGY CO., LTD

Jinan Aisi Pharmaceutical Technology Co., Ltd. was established in July 2010 with a registered capital of 22 million yuan. It is a specialized new type of pharmaceutical enterprise specializing in the technical development, technical services, technology transfer, production, and sales of chemical raw materials and pharmaceutical intermediates. It is a talent introduction enterprise under the "5150 Talent Plan" in Jinan City and a national high-tech enterprise. In 2022, it achieved a sales revenue of 102.3338 million yuan and a profit and tax of 1.3153 million yuan.
The company currently has over 60 employees, of which 70% have a bachelor's degree or above and 32 are directly engaged in research and development. The professional fields of team members almost cover all kinds of necessary professional knowledge in the research and development process. They have been engaged in Drug development, technical transformation and scientific and technological plan projects for a long time, with strong innovation ability, high scientific research level, and accumulated rich experience.
Peng Lizheng, the founder of the company, has been a doctor of organic chemistry of Lanzhou University, a researcher of engineering technology application, and an assistant researcher of the State Key Laboratory of Traditional Chinese Medicine Quality Research of Macau University of Science and Technology. He has been engaged in the research, development and production of new pharmaceutical products and intermediates for many years. I have successively led and participated in the research and development of more than ten new drugs, including faropenem sodium, sevoflurane, and tirofiban. The research results have received multiple new drug production approvals, and six have achieved the first or exclusive listing in China. Led and participated in the completion of three national level scientific research and construction projects, and undertaken one major science and technology special project for the 11th Five Year Plan of the Ministry of Science and Technology. As the main executor, Dr. Peng Lizheng has applied for a total of 66 domestic and foreign patents and granted 54 authorizations. Published 49 papers in important academic journals both domestically and internationally. Received 11 national, provincial, and municipal science and technology progress awards, including 2 national second prizes. Won the commemorative medal for the 70th anniversary of the founding of the People's Republic of China, the leading talent in science and technology entrepreneurship of the National Ten Thousand Talents Program, the leading talent in the National High level Talent Special Support Program, the scientific and technological innovation and entrepreneurship talent of the innovation talent promotion plan of the Ministry of Science and Technology, the leading talent in Mount Taishan industry, young and middle-aged experts with outstanding contributions in Shandong Province, the List of Chinese inventions Entrepreneurship Award, the Golden Bridge Award of the China Technology Market Association, and the 2022 Innovation and Promotion Award of China's Industry University Research Cooperation.
The company is equipped with modern analysis and testing equipment as well as experimental and production equipment. The Analysis and Testing Center is located in the Pharmaceutical Valley Industrial Park, Dazheng Road, Jinan High tech Zone. The laboratory is equipped with precision analysis instruments such as HPLC, GC, semi preparative and preparative liquid chromatography, differential scanning calorimeter, infrared spectrometer, atomic absorption spectrophotometer, etc; The pilot plant and industrialization base is located in the high-end raw material drug industrialization base of Shanghe Economic Development Zone in Jinan City, equipped with various types of reaction kettles, drug process research and control equipment, and other instruments and equipment.
Strong hardware equipment and strong technical strength ensure the smooth development of the company's new products. Since its development, the company has screened and researched nearly 100 products, such as Esomeprazole sodium/magnesium series products, Capecitabine intermediate, D-dihydronenenebc phenylglycine sodium sulfate, etc.
The company was recognized as a national high-tech enterprise in 2018, and has passed ISO9001 quality management system certification and GB/T 29490-2013 intellectual property management system certification. As of now, a total of 108 patents have been applied for,